Brief: RenovoRx, Imugene Announce Collaboration To Deliver Oncolytic Virus Therapy
20/07/2023 13:19
July 20 (Reuters) - Imugene Ltd IMU.AX :
* RENOVORX AND IMUGENE ANNOUNCE COLLABORATION TO DELIVER
ONCOLYTIC
VIRUS THERAPY USING PROPRIETARY TRANS-ARTERIAL MICRO-PERFUSION
(TAMP™) PLATFORM
* RENOVORX INC- COLLABORATION WILL EXPLORE TRANS-ARTERIAL
DELIVERY
OF IMUGENE'S CF33 ONCOLYTIC VIRUS UTILIZING RENOVORX'S TAMP
THERAPY PLATFORM.
Source text for Eikon: ID:nBw8rk6tca
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer